Stockreport

ProMIS Neurosciences Announces Third Quarter 2024 Financial Results and Recent Highlights

ProMIS Neurosciences Inc.  (PMN) 
PDF Presented full dataset from first-in-human Phase 1a clinical trial demonstrating PMN310 was generally well-tolerated with monthly dosing and that PMN310 demonstrated CSF [Read more]